This monthly feature presents questions from clinical trial professionals with answers from WCG experts. This month features insights from Institutional Biosafety Committee (IBC) Chair and Director of IBC Services Christopher Doyle. Read More

In this time of growing trial complexity, the use of patient advisory boards is critical to improving the patient and site trial experience — but just a small fraction of protocols currently use them, according to two WCG experts. Read More

The clinical research industry is falling behind the innovation curve, says Ken Getz, executive director of the Tufts Center for the Study of Drug Development (CSDD), taking years — and sometimes decades — to evaluate, adopt and fully implement new technologies and methods. Read More

The University of North Carolina at Chapel Hill (UNC) School of Medicine’s innovative web-based solution to managing their trials’ startup processes was crowned the winner of this year’s Innovation Challenge at the 2023 MAGI East Clinical Research Conference in Philadelphia. Read More

Great progress has been made in the movement to improve diversity, equity and inclusion (DE&I) in clinical research, but experts say more work is needed improving trust and scaling down to the community level to continue making strides. Read More

Sponsors should build risk-based quality management (RBQM) into their trials as if they were constructing a house from the basement up, advises the director of the FDA’s Office of Bioresearch Monitoring Operations. Read More

The scope and burden of conducting late-stage trials is rapidly growing, research from Tufts University’s Center for the Study of Drug Development (CSDD) finds, with the average number of phase 3 endpoints having increased 37 percent since 2015. Read More

The carbon footprint of clinical research is an important metric for sites and sponsors to understand, say two Janssen directors who will present new data on trial sustainability at the 2023 MAGI East Clinical Research Conference next week. Read More